Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free CLDX Stock Alerts

Celldex Therapeutics (CLDX) Financials

Celldex Therapeutics logo
$31.60 +0.75 (+2.42%)
As of 01:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Celldex Therapeutics

Annual Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Consolidated Net Income / (Loss)		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Net Income / (Loss) Continuing Operations		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Total Pre-Tax Income 		-127 -129 -117 -152 -51 -61 -71 -112 -141 -158 -259
Total Operating Income		 -130 -133 -122 -156 -55 -63 -71 -115 -155 -195 -287
Total Gross Profit		 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02 1.55
Total Revenue		 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02 1.55
Operating Revenue		 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02 1.55
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 135 140 134 166 59 71 76 118 161 202 289
Selling, General & Admin Expense		 34 36 25 19 15 14 20 27 31 39 44
Research & Development Expense		 100 103 96 66 43 43 53 82 118 164 245
Other Special Charges / (Income)		 - - - - - 0.00 0.00 15 13 0.00 0.00
Total Other Income / (Expense), net		 2.34 4.39 4.21 4.49 4.15 2.41 0.51 2.91 13 37 29
Interest & Investment Income		 2.34 4.39 4.21 4.49 4.15 2.41 0.51 2.91 13 37 29
Basic Earnings per Share		 ($1.31) ($18.99) ($10.86) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Weighted Average Basic Shares Outstanding		 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 42.87M 46.89M 48.45M 64.40M 66.42M
Diluted Earnings per Share		 ($1.31) ($18.99) ($10.86) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Weighted Average Diluted Shares Outstanding		 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 42.87M 46.89M 48.45M 64.40M 66.42M
Weighted Average Basic & Diluted Shares Outstanding		 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 46.74M 47.21M 55.90M 66.38M 66.57M

Quarterly Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -38 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79
Consolidated Net Income / (Loss)		 -38 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79
Net Income / (Loss) Continuing Operations		 -38 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79
Total Pre-Tax Income 		0.00 -141 -33 -36 -42 -158 -54 -57 -67 -81 -79
Total Operating Income		 -41 -48 -41 -46 -52 -56 -63 -64 -74 -87 -84
Total Gross Profit		 1.52 4.13 0.16 2.50 3.19 1.18 0.70 0.73 0.00 0.12 0.02
Total Revenue		 1.52 4.13 0.16 2.50 3.19 1.18 0.70 0.73 0.00 0.12 0.02
Operating Revenue		 1.52 4.13 0.16 2.50 3.19 1.18 0.70 0.73 0.00 0.12 0.02
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 43 52 41 49 55 57 63 65 74 87 84
Selling, General & Admin Expense		 8.22 8.83 9.10 9.13 10 10 11 10 11 12 11
Research & Development Expense		 35 30 32 40 45 47 53 54 63 75 73
Total Other Income / (Expense), net		 2.98 4.32 7.80 10 10 8.94 8.94 7.26 6.57 5.84 5.75
Interest & Investment Income		 2.98 4.32 7.80 10 10 8.94 8.94 7.26 6.57 5.84 5.75
Basic Earnings per Share		 ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18)
Weighted Average Basic Shares Outstanding		 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M
Diluted Earnings per Share		 ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18)
Weighted Average Diluted Shares Outstanding		 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M
Weighted Average Basic & Diluted Shares Outstanding		 47.26M 55.90M 65.91M 66.29M 66.34M 66.38M 66.39M 66.41M 66.45M 66.57M 78.49M

Annual Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 44 -30 -2.17 -16 -13 33 -4.69 -9.71 5.39 -6.46 0.52
Net Cash From Operating Activities		 -99 -113 -100 -75 -46 -40 -61 -104 -107 -158 -211
Net Cash From Continuing Operating Activities		 -99 -113 -100 -75 -46 -40 -61 -104 -107 -158 -211
Net Income / (Loss) Continuing Operations		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Consolidated Net Income / (Loss)		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Depreciation Expense		 3.00 3.10 4.41 3.58 4.86 3.93 3.07 2.90 3.01 3.18 3.38
Amortization Expense		 1.65 3.56 1.19 -0.82 -1.14 -0.73 -3.21 0.84 -6.22 -16 -5.86
Non-Cash Adjustments To Reconcile Net Income		 13 15 0.98 89 5.07 21 12 16 24 34 36
Changes in Operating Assets and Liabilities, net		 11 -6.56 -13 -15 -4.32 -4.52 -2.46 -11 13 -22 14
Net Cash From Investing Activities		 -50 69 46 30 17 -98 -216 90 -106 -290 209
Net Cash From Continuing Investing Activities		 -50 69 46 30 17 -98 -216 90 -106 -290 209
Purchase of Property, Plant & Equipment		 -4.88 -2.75 -1.79 -0.81 -0.73 -1.55 -1.25 -1.83 -1.82 -1.92 -2.71
Purchase of Investments		 -206 -176 -171 -171 -95 -220 -390 -189 -425 -790 -385
Sale and/or Maturity of Investments		 161 243 219 201 113 124 175 281 321 502 596
Other Investing Activities, net		 - - - - - - -0.29 -0.11 -0.08 -0.03 -0.10
Net Cash From Financing Activities		 193 14 51 29 16 171 272 4.08 218 441 2.39
Net Cash From Continuing Financing Activities		 193 14 51 29 16 171 272 4.08 218 441 2.39
Issuance of Common Equity		 193 14 51 29 16 171 272 4.08 218 441 2.39

Quarterly Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -7.09 14 80 -72 -6.34 -8.04 -11 5.91 13 -7.17 6.86
Net Cash From Operating Activities		 -19 -33 -41 -29 -55 -32 -54 -44 -49 -64 -66
Net Cash From Continuing Operating Activities		 -19 -33 -41 -29 -55 -32 -54 -44 -49 -64 -66
Net Income / (Loss) Continuing Operations		 -38 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79
Consolidated Net Income / (Loss)		 -38 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79
Depreciation Expense		 0.77 0.76 0.78 0.80 0.79 0.82 0.87 0.87 0.82 0.82 0.85
Amortization Expense		 -1.63 -2.18 -3.31 -4.74 -4.33 -3.36 -2.27 -1.69 -1.02 -0.88 -0.63
Non-Cash Adjustments To Reconcile Net Income		 7.12 7.21 7.21 7.64 9.62 9.78 9.32 9.19 8.81 8.91 8.53
Changes in Operating Assets and Liabilities, net		 13 4.98 -13 2.82 -19 7.38 -8.50 4.22 9.80 8.53 4.35
Net Cash From Investing Activities		 12 -171 -315 -47 48 24 43 50 61 55 72
Net Cash From Continuing Investing Activities		 11 -171 -315 -47 48 24 43 50 60 56 72
Purchase of Property, Plant & Equipment		 -0.16 -0.67 -0.34 -0.27 -0.55 -0.76 -0.27 -0.73 -0.44 -1.28 -1.64
Purchase of Investments		 -28 -241 -392 -169 -100 -129 -152 -122 -56 -55 -60
Sale and/or Maturity of Investments		 40 71 77 122 148 154 195 173 117 112 133
Net Cash From Financing Activities		 0.26 217 436 3.71 1.24 0.39 0.20 0.06 0.77 1.35 0.33
Net Cash From Continuing Financing Activities		 0.26 217 436 3.71 1.24 0.39 0.20 0.06 0.77 1.35 0.33
Issuance of Common Equity		 0.26 217 436 3.71 1.24 0.39 0.20 0.06 0.77 1.35 0.33

Annual Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 338 383 316 156 123 236 445 353 466 792 583
Total Current Assets		 295 196 145 99 67 198 411 318 432 747 535
Cash & Equivalents		 72 42 40 24 11 44 39 29 35 28 29
Short-Term Investments		 218 147 99 70 53 151 369 276 389 697 490
Accounts Receivable		 0.97 1.78 1.88 3.16 1.02 1.80 0.17 0.35 2.63 0.70 2.02
Prepaid Expenses		 4.08 4.01 3.45 1.90 1.30 1.62 2.42 12 5.47 21 14
Plant, Property, & Equipment, net		 11 13 10 6.11 4.03 3.82 3.55 3.75 4.06 4.35 5.33
Total Noncurrent Assets		 31 175 160 51 52 34 30 31 30 41 43
Intangible Assets		 21 81 68 49 49 31 27 27 27 27 27
Other Noncurrent Operating Assets		 1.43 2.13 1.93 1.93 3.51 3.49 3.07 4.11 2.68 14 16
Total Liabilities & Shareholders' Equity		 338 383 316 156 123 236 445 353 466 792 583
Total Liabilities		 47 118 79 32 29 26 25 27 36 45 56
Total Current Liabilities		 30 35 28 13 12 14 17 19 31 40 51
Accounts Payable		 1.51 1.74 1.72 1.07 1.17 1.05 1.23 3.34 3.49 3.27 1.18
Accrued Expenses		 24 29 19 7.01 6.50 8.46 12 13 22 34 47
Other Current Liabilities		 4.42 4.83 6.57 4.53 3.97 4.70 3.30 2.44 5.60 2.39 2.78
Total Noncurrent Liabilities		 17 83 52 19 17 12 8.65 7.92 5.33 5.83 4.83
Other Noncurrent Operating Liabilities		 17 83 52 19 17 12 8.65 7.92 5.33 5.83 4.83
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 290 265 236 124 94 209 419 326 429 747 527
Total Preferred & Common Equity		 290 265 236 124 94 209 419 326 429 747 527
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 290 265 236 124 94 209 419 326 429 747 527
Common Stock		 879 982 1,046 1,084 1,105 1,280 1,561 1,581 1,823 2,299 2,338
Retained Earnings		 -591 -719 -813 -962 -1,013 -1,073 -1,144 -1,256 -1,397 -1,555 -1,814
Accumulated Other Comprehensive Income / (Loss)		 2.31 2.54 2.56 2.58 2.62 2.59 1.89 1.26 3.31 3.31 3.63

Quarterly Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 369 325 299 280 869 846 823 739 692 648 511
Total Current Assets		 335 290 265 246 835 812 779 694 648 604 459
Cash & Equivalents		 19 54 28 21 115 43 36 17 23 36 36
Short-Term Investments		 305 224 224 214 709 760 720 656 607 547 416
Accounts Receivable		 0.19 1.31 0.12 0.25 2.67 1.53 0.85 1.06 0.09 0.09 0.23
Prepaid Expenses		 11 9.90 12 10 8.81 8.12 22 19 18 21 7.53
Plant, Property, & Equipment, net		 3.75 4.00 3.94 4.16 4.06 3.86 4.23 4.60 4.39 4.83 7.40
Total Noncurrent Assets		 31 31 31 30 29 30 40 41 40 39 45
Intangible Assets		 27 27 27 27 27 27 27 27 27 27 27
Other Noncurrent Operating Assets		 3.68 3.74 3.36 2.97 2.27 2.56 13 14 12 12 17
Total Liabilities & Shareholders' Equity		 369 325 299 280 869 846 823 739 692 648 511
Total Liabilities		 24 22 22 34 30 32 37 36 37 50 55
Total Current Liabilities		 16 15 16 28 26 28 32 32 33 46 51
Accounts Payable		 2.27 3.37 0.88 3.59 3.23 3.80 1.11 3.41 2.07 4.27 10
Accrued Expenses		 11 9.37 12 18 18 19 28 25 28 40 38
Other Current Liabilities		 2.59 2.47 2.51 5.78 5.52 5.26 2.78 3.15 2.47 2.48 2.70
Total Noncurrent Liabilities		 7.52 6.56 6.13 5.70 3.94 4.27 5.18 4.47 4.04 3.61 3.56
Other Noncurrent Operating Liabilities		 7.52 6.56 6.13 5.70 3.94 4.27 5.18 4.47 4.04 3.61 3.56
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 345 303 278 247 839 814 786 703 655 598 456
Total Preferred & Common Equity		 345 303 278 247 839 814 786 703 655 598 456
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 345 303 278 247 839 814 786 703 655 598 456
Common Stock		 1,575 1,586 1,591 1,599 2,267 2,278 2,289 2,308 2,318 2,327 2,346
Retained Earnings		 -1,229 -1,285 -1,316 -1,354 -1,430 -1,466 -1,508 -1,609 -1,666 -1,733 -1,893
Accumulated Other Comprehensive Income / (Loss)		 -0.11 2.12 2.07 2.14 2.24 1.78 5.29 3.57 3.34 3.77 2.52

Annual Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 52.82% 23.83% 87.78% -25.15% -62.54% 107.61% -37.30% -49.32% 192.02% 1.99% -77.99%
EBITDA Growth		 -5.07% -1.10% 8.18% -32.57% 66.61% -17.23% -18.67% -56.19% -41.49% -31.63% -39.58%
EBIT Growth		 -5.81% -2.61% 8.57% -28.73% 64.82% -15.12% -12.45% -61.75% -34.11% -26.23% -47.31%
NOPAT Growth		 -5.81% -2.61% 8.57% -28.73% 64.82% -15.12% -12.45% -61.75% -34.11% -26.23% -47.31%
Net Income Growth		 -7.72% -1.05% 27.62% -62.51% 66.35% -17.50% -17.95% -59.30% -25.91% -11.62% -63.91%
EPS Growth		 0.76% -1.05% 27.62% -62.51% 75.76% 42.45% 18.81% -46.34% -21.67% 16.10% -59.18%
Operating Cash Flow Growth		 2.61% -14.31% 11.59% 24.71% 38.31% 12.95% -50.75% -70.31% -3.43% -47.06% -33.70%
Free Cash Flow Firm Growth		 -0.97% -109.87% 36.87% 59.94% 10.50% 22.26% -55.74% -96.46% -2.00% -65.09% -23.13%
Invested Capital Growth		 -97.97% 34,925.46% 28.14% -69.01% -1.32% -49.62% -24.83% 89.31% -73.78% 289.81% -60.45%
Revenue Q/Q Growth		 6.06% 1.25% 14.17% -15.05% -19.74% 64.15% -42.61% 118.85% 57.69% -29.63% -40.58%
EBITDA Q/Q Growth		 -0.94% -0.43% 6.56% 7.26% -4.44% -20.83% 6.51% -8.12% -15.62% -4.81% -10.97%
EBIT Q/Q Growth		 -1.08% -1.08% 7.13% 7.89% -1.60% -22.87% 5.87% -7.01% -14.65% -4.50% -12.15%
NOPAT Q/Q Growth		 -1.08% -1.08% 7.13% 7.89% -1.60% -22.87% 5.87% -7.01% -14.65% -4.50% -12.15%
Net Income Q/Q Growth		 -0.68% 0.29% 23.43% -3.82% -2.10% -23.70% 2.42% -5.98% -13.50% -2.46% -15.24%
EPS Q/Q Growth		 2.24% 0.29% 23.43% -3.82% -7.67% -64.23% -3.14% -6.19% -10.19% 5.04% -15.38%
Operating Cash Flow Q/Q Growth		 7.89% -6.20% 0.82% 5.16% 8.71% 12.53% -18.05% -7.50% -11.16% 0.04% -17.53%
Free Cash Flow Firm Q/Q Growth		 9.22% -83.37% 31.99% 32.14% 13.07% 22.03% -27.45% -8.35% -10.40% -2.34% -14.23%
Invested Capital Q/Q Growth		 -98.46% 446.48% 23.30% 33.41% 4.15% -50.84% -17.60% -3.16% -50.99% -27.36% -43.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,279.05% -1,860.60% -909.73% -1,611.27% -1,436.13% -810.92% -1,534.81% -4,730.34% -2,291.97% -2,957.98% -18,760.00%
Operating Margin		 -2,363.89% -1,958.68% -953.68% -1,640.13% -1,540.19% -854.06% -1,531.78% -4,889.01% -2,245.27% -2,778.89% -18,599.81%
EBIT Margin		 -2,363.89% -1,958.68% -953.68% -1,640.13% -1,540.19% -854.06% -1,531.78% -4,889.01% -2,245.27% -2,778.89% -18,599.81%
Profit (Net Income) Margin		 -2,321.11% -1,894.05% -730.06% -1,585.07% -1,423.96% -805.88% -1,516.04% -4,765.59% -2,054.76% -2,248.76% -16,748.03%
Tax Burden Percent		 100.00% 100.00% 79.30% 99.50% 100.00% 98.09% 99.68% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.19% 96.70% 96.53% 97.13% 92.45% 96.20% 99.29% 97.48% 91.51% 80.92% 90.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,674.12% -245.26% -98.58% -172.48% -129.09% -198.97% -381.26% -496.73% -806.56% -1,000.51% -1,327.07%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,659.24% -230.46% -93.74% -136.77% -113.49% -187.04% -374.41% -487.85% -797.43% -996.80% -1,317.81%
Return on Net Nonoperating Assets (RNNOA)		 1,623.42% 198.99% 61.50% 88.59% 82.43% 159.56% 358.83% 466.60% 769.11% 973.67% 1,286.45%
Return on Equity (ROE)		 -50.70% -46.27% -37.08% -83.89% -46.66% -39.41% -22.43% -30.13% -37.45% -26.84% -40.62%
Cash Return on Invested Capital (CROIC)		 -1,482.10% -444.12% -123.24% -67.10% -127.77% -132.98% -352.90% -558.47% -689.66% -1,118.85% -1,240.43%
Operating Return on Assets (OROA)		 -44.24% -36.87% -34.77% -66.37% -39.49% -35.32% -20.94% -28.90% -37.77% -31.01% -41.79%
Return on Assets (ROA)		 -43.44% -35.66% -26.62% -64.14% -36.51% -33.32% -20.72% -28.17% -34.56% -25.10% -37.63%
Return on Common Equity (ROCE)		 -50.70% -46.27% -37.08% -83.89% -46.66% -39.41% -22.43% -30.13% -37.45% -26.84% -40.62%
Return on Equity Simple (ROE_SIMPLE)		 -43.85% -48.42% -39.36% -121.86% -54.11% -28.55% -16.81% -34.43% -32.95% -21.13% 0.00%
Net Operating Profit after Tax (NOPAT)		 -91 -93 -85 -110 -39 -44 -50 -81 -108 -137 -201
NOPAT Margin		 -1,654.72% -1,371.08% -667.57% -1,148.09% -1,078.13% -597.84% -1,072.24% -3,422.31% -1,571.69% -1,945.22% -13,019.86%
Net Nonoperating Expense Percent (NNEP)		 -14.88% -14.80% -4.84% -35.71% -15.60% -11.93% -6.85% -8.88% -9.13% -3.71% -9.26%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -24.73% -25.21% -18.28% -38.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 617.46% 530.19% 196.21% 202.02% 431.74% 194.88% 440.51% 1,153.80% 449.14% 549.12% 2,837.41%
R&D to Revenue		 1,827.94% 1,513.79% 754.70% 696.68% 1,194.29% 573.39% 1,146.23% 3,489.94% 1,714.53% 2,329.77% 15,862.39%
Operating Expenses to Revenue		 2,463.89% 2,058.68% 1,053.68% 1,740.13% 1,640.19% 954.06% 1,631.78% 4,989.01% 2,345.27% 2,878.89% 18,699.81%
Earnings before Interest and Taxes (EBIT)		 -130 -133 -122 -156 -55 -63 -71 -115 -155 -195 -287
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -125 -126 -116 -154 -51 -60 -71 -111 -158 -208 -290
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.33 1.35 1.63 0.28 0.38 3.31 4.30 6.44 4.37 2.24 3.42
Price to Tangible Book Value (P/TBV)		 5.94 3.86 4.96 0.45 0.79 3.88 4.60 7.02 4.66 2.33 3.61
Price to Revenue (P/Rev)		 282.26 52.82 30.31 3.58 10.07 93.45 387.68 890.64 272.34 238.82 1,168.13
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5,818.87 2.23 2.55 0.00 0.00 33.40 124.25 84.43 260.34 43.79 149.70
Enterprise Value to Revenue (EV/Rev)		 229.36 24.85 19.37 0.00 0.00 67.24 299.90 761.26 210.79 135.50 832.49
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.86 -0.66 -0.65 -0.73 -0.85 -0.96 -0.96 -0.96 -0.98 -0.98
Leverage Ratio		 1.17 1.30 1.39 1.31 1.28 1.18 1.08 1.07 1.08 1.07 1.08
Compound Leverage Factor		 1.15 1.25 1.34 1.27 1.18 1.14 1.07 1.04 0.99 0.87 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 16.79 -1.43 -1.47 -10.59 -11.70 9.42 39.91 42.44 26.60 19.71 14.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.75 5.55 5.22 7.86 5.73 13.93 24.86 17.07 13.87 18.91 10.49
Quick Ratio		 9.62 5.44 5.09 7.71 5.62 13.81 24.71 16.41 13.69 18.38 10.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -80 -168 -106 -43 -38 -30 -46 -91 -93 -153 -188
Operating Cash Flow to CapEx		 -2,028.04% -4,108.91% -5,588.98% -15,973.46% -6,528.13% -2,699.00% -4,984.37% -5,897.21% -5,901.60% -8,221.89% -7,772.48%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.04 0.04 0.03 0.04 0.01 0.01 0.02 0.01 0.00
Accounts Receivable Turnover		 7.85 4.93 6.96 3.78 1.71 5.27 4.71 9.08 4.63 4.22 1.14
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.50 0.55 1.08 1.16 0.70 1.89 1.26 0.65 1.76 1.67 0.32
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 46.52 74.07 52.47 96.47 213.35 69.30 77.46 40.19 78.88 86.52 320.70
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 46.52 74.07 52.47 96.47 213.35 69.30 77.46 40.19 78.88 86.52 320.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.22 76 97 30 30 15 11 21 5.57 22 8.59
Invested Capital Turnover		 1.01 0.18 0.15 0.15 0.12 0.33 0.36 0.15 0.51 0.51 0.10
Increase / (Decrease) in Invested Capital		 -10 75 21 -67 -0.40 -15 -3.71 10 -16 16 -13
Enterprise Value (EV)		 1,257 169 247 -60 -28 499 1,395 1,794 1,451 951 1,286
Market Capitalization		 1,547 358 386 34 36 693 1,803 2,099 1,874 1,677 1,805
Book Value per Share		 $2.94 $2.62 $1.74 $0.72 $5.83 $5.29 $8.99 $6.93 $9.08 $11.26 $7.93
Tangible Book Value per Share		 $2.64 $0.92 $0.57 $0.44 $2.81 $4.52 $8.41 $6.35 $8.51 $10.85 $7.52
Total Capital		 290 265 236 124 94 209 419 326 429 747 527
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -290 -190 -139 -94 -64 -194 -408 -305 -424 -725 -519
Capital Expenditures (CapEx)		 4.88 2.75 1.79 0.47 0.71 1.50 1.22 1.76 1.82 1.92 2.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -29 -22 -7.55 -9.33 -11 -14 -5.87 -23 -18 -35
Debt-free Net Working Capital (DFNWC)		 265 160 117 86 55 184 394 299 401 708 484
Net Working Capital (NWC)		 265 160 117 86 55 184 394 299 401 708 484
Net Nonoperating Expense (NNE)		 37 35 7.96 42 12 15 21 32 33 21 58
Net Nonoperating Obligations (NNO)		 -290 -190 -139 -94 -64 -194 -408 -305 -424 -725 -519
Total Depreciation and Amortization (D&A)		 4.65 6.66 5.60 2.75 3.72 3.20 -0.14 3.74 -3.21 -13 -2.48
Debt-free, Cash-free Net Working Capital to Revenue		 -459.73% -433.69% -175.84% -79.10% -261.07% -145.39% -299.70% -249.00% -334.59% -251.04% -2,258.90%
Debt-free Net Working Capital to Revenue		 4,830.22% 2,362.89% 918.31% 906.66% 1,540.86% 2,475.56% 8,477.98% 12,689.14% 5,819.67% 10,080.60% 31,305.70%
Net Working Capital to Revenue		 4,830.22% 2,362.89% 918.31% 906.66% 1,540.86% 2,475.56% 8,477.98% 12,689.14% 5,819.67% 10,080.60% 31,305.70%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Adjusted Weighted Average Basic Shares Outstanding		 6.58M 8.21M 9.40M 12.44M 17.57M 39.61M 42.87M 46.89M 48.45M 64.40M 66.42M
Adjusted Diluted Earnings per Share		 ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Adjusted Weighted Average Diluted Shares Outstanding		 6.58M 8.21M 9.40M 12.44M 17.57M 39.61M 42.87M 46.89M 48.45M 64.40M 66.42M
Adjusted Basic & Diluted Earnings per Share		 ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.47M 6.77M 8.57M 10.44M 14.51M 29.64M 46.74M 47.21M 55.90M 66.38M 66.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -91 -93 -76 -33 -37 -32 -47 -70 -99 -137 -201
Normalized NOPAT Margin		 -1,654.72% -1,371.08% -596.16% -343.34% -1,042.87% -427.98% -1,019.57% -2,976.83% -1,444.56% -1,945.22% -13,019.86%
Pre Tax Income Margin		 -2,321.11% -1,894.05% -920.61% -1,593.09% -1,423.96% -821.61% -1,520.92% -4,765.59% -2,054.76% -2,248.76% -16,748.03%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 66,566,346.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 66,566,346.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.18
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 272.73% 156.11% -83.87% 832.09% 110.35% -71.56% 345.51% -70.78% -100.00% -89.79% -97.84%
EBITDA Growth		 -56.11% -76.85% -30.74% -49.54% -32.24% -19.42% -48.66% -28.67% -32.58% -48.91% -31.29%
EBIT Growth		 -48.90% -70.80% -25.06% -39.49% -26.40% -17.64% -54.50% -37.87% -41.23% -55.56% -34.58%
NOPAT Growth		 -48.90% -70.80% -25.06% -39.49% -26.40% -17.64% -54.50% -37.87% -41.23% -55.56% -34.58%
Net Income Growth		 -42.85% -63.50% -11.74% -17.51% -10.09% -8.74% -63.97% -57.92% -59.17% -72.68% -46.27%
EPS Growth		 -42.11% -47.37% 9.68% 16.92% 20.99% 15.48% -44.64% -57.41% -57.81% -73.24% -45.68%
Operating Cash Flow Growth		 46.03% -49.49% -42.25% -7.84% -191.35% 0.18% -33.80% -50.05% 12.12% -96.88% -20.63%
Free Cash Flow Firm Growth		 33.98% 40.23% 36.03% 52.46% -200.81% -213.53% -212.32% -208.75% 33.18% 13.53% 41.91%
Invested Capital Growth		 -48.19% -73.78% -39.36% -54.34% 163.03% 289.81% 101.06% 121.03% -49.37% -60.45% -83.94%
Revenue Q/Q Growth		 466.04% 172.31% -96.22% 1,501.28% 27.74% -63.18% -40.85% 5.04% -100.00% 0.00% -87.50%
EBITDA Q/Q Growth		 -25.26% -16.50% 12.03% -16.49% -10.77% -5.21% -9.51% -0.83% -14.13% -18.17% 3.45%
EBIT Q/Q Growth		 -24.20% -15.49% 14.74% -14.06% -12.54% -7.48% -11.98% -1.78% -15.28% -18.39% 3.12%
NOPAT Q/Q Growth		 -24.20% -15.49% 14.74% -14.06% -12.54% -7.48% -11.98% -1.78% -15.28% -18.39% 3.12%
Net Income Q/Q Growth		 -25.43% -13.19% 24.24% -9.25% -17.52% -11.80% -14.24% -5.21% -18.45% -21.29% 3.24%
EPS Q/Q Growth		 -24.62% -3.70% 33.33% 3.57% -18.52% -10.94% -14.08% -4.94% -18.82% -21.78% 4.07%
Operating Cash Flow Q/Q Growth		 30.16% -71.29% -24.91% 27.83% -88.69% 41.31% -67.42% 19.07% -10.51% -31.49% -2.58%
Free Cash Flow Firm Q/Q Growth		 54.05% 3.46% -6.68% -0.45% -190.77% -0.63% -6.27% 0.70% 37.07% -30.22% 28.60%
Invested Capital Q/Q Growth		 -54.23% -50.99% 164.97% -23.19% 163.67% -27.36% 36.67% -15.56% -39.61% -43.25% -44.51%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00%
EBITDA Margin		 -2,775.15% -1,187.29% -27,657.69% -2,012.01% -1,744.69% -4,984.77% -9,228.63% -8,859.18% 0.00% -72,683.33% -561,406.67%
Operating Margin		 -2,718.46% -1,152.92% -26,030.77% -1,854.16% -1,633.53% -4,768.26% -9,027.19% -8,747.53% 0.00% -72,628.33% -562,900.00%
EBIT Margin		 -2,718.46% -1,152.92% -26,030.77% -1,854.16% -1,633.53% -4,768.26% -9,027.19% -8,747.53% 0.00% -72,628.33% -562,900.00%
Profit (Net Income) Margin		 -2,522.08% -1,048.32% -21,030.77% -1,434.83% -1,319.99% -4,007.83% -7,740.43% -7,753.42% 0.00% -67,764.17% -524,566.67%
Tax Burden Percent		 0.00% 30.62% 100.00% 0.00% 0.00% 29.83% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 0.00% 296.95% 80.79% 0.00% 0.00% 281.76% 85.75% 88.64% 91.07% 93.30% 93.19%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -498.65% -414.16% -5,656.50% -595.62% -552.73% -1,716.76% -2,148.84% -1,947.76% 0.00% -5,181.92% -19,782.69%
ROIC Less NNEP Spread (ROIC-NNEP)		 -495.29% -411.42% -5,655.71% -594.97% -551.60% -1,715.39% -2,147.53% -1,946.10% 0.00% -5,178.65% -19,779.21%
Return on Net Nonoperating Assets (RNNOA)		 467.42% 396.81% 5,461.86% 575.24% 529.55% 1,675.58% 2,085.59% 1,897.86% 0.00% 5,055.44% 19,191.26%
Return on Equity (ROE)		 -31.23% -17.35% -194.65% -20.38% -23.18% -41.18% -63.25% -49.90% 0.00% -126.48% -591.43%
Cash Return on Invested Capital (CROIC)		 -502.99% -689.66% -533.18% -605.58% -722.99% -1,118.85% -751.15% -978.01% -730.82% -1,240.43% -1,111.05%
Operating Return on Assets (OROA)		 -36.54% -19.39% -264.90% -26.89% -29.54% -53.22% -84.85% -65.87% 0.00% -163.18% -778.60%
Return on Assets (ROA)		 -33.90% -17.63% -214.01% -20.81% -23.87% -44.73% -72.76% -58.39% 0.00% -152.25% -725.58%
Return on Common Equity (ROCE)		 -31.23% -17.35% -194.65% -20.38% -23.18% -41.18% -63.25% -49.90% 0.00% -126.48% -591.43%
Return on Equity Simple (ROE_SIMPLE)		 -50.51% 0.00% -17.28% -18.46% -19.61% 0.00% -25.44% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -29 -33 -28 -32 -36 -39 -44 -45 -52 -61 -59
NOPAT Margin		 -1,902.92% -807.04% -18,221.54% -1,297.91% -1,143.47% -3,337.78% -6,319.04% -6,123.27% 0.00% -50,839.83% -394,030.00%
Net Nonoperating Expense Percent (NNEP)		 -3.36% -2.74% -0.80% -0.65% -1.14% -1.37% -1.32% -1.66% -2.32% -3.27% -3.48%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.77% -3.39% - - -5.25% -6.25% -6.82% -8.61% -11.57% -12.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 541.92% 213.80% 5,835.26% 365.41% 315.07% 873.45% 1,556.83% 1,423.42% 0.00% 9,950.83% 76,326.67%
R&D to Revenue		 2,276.53% 736.53% 20,295.51% 1,588.75% 1,418.46% 3,994.81% 7,570.36% 7,424.11% 0.00% 62,777.50% 486,673.33%
Operating Expenses to Revenue		 2,818.46% 1,252.92% 26,130.77% 1,954.16% 1,733.53% 4,868.26% 9,127.19% 8,847.53% 0.00% 72,728.33% 563,000.00%
Earnings before Interest and Taxes (EBIT)		 -41 -48 -41 -46 -52 -56 -63 -64 -74 -87 -84
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -42 -49 -43 -50 -56 -59 -64 -65 -74 -87 -84
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.27 4.37 2.37 3.00 2.87 2.24 1.71 2.06 2.87 3.42 4.63
Price to Tangible Book Value (P/TBV)		 5.92 4.66 2.44 3.10 2.97 2.33 1.78 2.15 3.01 3.61 4.92
Price to Revenue (P/Rev)		 297.97 272.34 326.69 293.83 225.85 238.82 159.39 233.31 660.75 1,168.13 2,441.02
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 93.69 260.34 78.54 144.33 50.06 43.79 17.90 28.75 74.95 149.70 348.16
Enterprise Value to Revenue (EV/Rev)		 244.05 210.79 191.01 197.19 150.07 135.50 70.32 124.47 436.43 832.49 1,919.11
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.94 -0.96 -0.97 -0.97 -0.96 -0.98 -0.97 -0.98 -0.97 -0.98 -0.97
Leverage Ratio		 1.10 1.08 1.05 1.05 1.07 1.07 1.04 1.05 1.06 1.08 1.08
Compound Leverage Factor		 0.00 3.22 0.84 0.00 0.00 3.01 0.89 0.93 0.97 1.01 1.01
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 16.97 27.36 38.03 44.36 34.60 20.29 17.57 19.31 17.50 15.55 18.25
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.84 13.87 31.77 29.36 24.27 18.91 21.67 19.67 13.01 10.49 8.92
Quick Ratio		 8.46 13.69 31.44 29.06 23.58 18.38 21.06 19.13 12.55 10.21 8.78
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -18 -19 -19 -55 -55 -59 -58 -37 -48 -34
Operating Cash Flow to CapEx		 -12,097.45% -4,884.83% -11,813.37% -10,703.28% -10,153.58% -4,295.77% -20,517.74% -6,044.64% -11,051.82% -4,991.41% -4,001.71%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.00 0.00
Accounts Receivable Turnover		 19.80 4.63 3.05 10.05 18.07 4.22 4.05 7.13 5.52 1.14 1.34
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.10 1.76 1.51 2.13 2.38 1.67 1.75 1.40 0.57 0.32 0.14
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 18.44 78.88 119.77 36.32 20.20 86.52 90.18 51.18 66.12 320.70 273.01
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 18.44 78.88 119.77 36.32 20.20 86.52 90.18 51.18 66.12 320.70 273.01
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 11 5.57 15 11 30 22 30 25 15 8.59 4.77
Invested Capital Turnover		 0.26 0.51 0.31 0.46 0.48 0.51 0.34 0.32 0.12 0.10 0.05
Increase / (Decrease) in Invested Capital		 -11 -16 -9.59 -13 19 16 15 14 -15 -13 -25
Enterprise Value (EV)		 1,065 1,451 1,160 1,637 1,497 951 532 721 1,135 1,286 1,660
Market Capitalization		 1,301 1,874 1,984 2,439 2,253 1,677 1,205 1,351 1,718 1,805 2,111
Book Value per Share		 $5.22 $9.08 $14.24 $12.34 $11.86 $11.26 $10.59 $9.87 $9.01 $7.93 $6.85
Tangible Book Value per Share		 $4.65 $8.51 $13.78 $11.93 $11.45 $10.85 $10.18 $9.46 $8.60 $7.52 $6.45
Total Capital		 247 429 839 814 786 747 703 655 598 527 456
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -235 -424 -824 -802 -756 -725 -673 -630 -583 -519 -451
Capital Expenditures (CapEx)		 0.16 0.67 0.34 0.27 0.55 0.76 0.27 0.73 0.44 1.28 1.64
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -17 -23 -15 -18 -9.25 -18 -12 -15 -25 -35 -44
Debt-free Net Working Capital (DFNWC)		 218 401 809 784 747 708 662 615 558 484 408
Net Working Capital (NWC)		 218 401 809 784 747 708 662 615 558 484 408
Net Nonoperating Expense (NNE)		 9.39 9.97 4.38 3.42 5.63 7.87 9.88 12 16 20 20
Net Nonoperating Obligations (NNO)		 -235 -424 -824 -802 -756 -725 -673 -630 -583 -519 -451
Total Depreciation and Amortization (D&A)		 -0.86 -1.42 -2.54 -3.94 -3.55 -2.54 -1.40 -0.82 -0.19 -0.07 0.22
Debt-free, Cash-free Net Working Capital to Revenue		 -395.21% -334.59% -243.96% -216.82% -92.72% -251.04% -152.82% -257.23% -974.96% -2,258.90% -5,052.95%
Debt-free Net Working Capital to Revenue		 4,996.49% 5,819.67% 13,324.00% 9,447.33% 7,485.46% 10,080.60% 8,754.32% 10,627.54% 21,456.69% 31,305.70% 47,138.73%
Net Working Capital to Revenue		 4,996.49% 5,819.67% 13,324.00% 9,447.33% 7,485.46% 10,080.60% 8,754.32% 10,627.54% 21,456.69% 31,305.70% 47,138.73%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18)
Adjusted Weighted Average Basic Shares Outstanding		 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M
Adjusted Diluted Earnings per Share		 ($0.81) ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18)
Adjusted Weighted Average Diluted Shares Outstanding		 47.26M 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 47.26M 55.90M 65.91M 66.29M 66.34M 66.38M 66.39M 66.41M 66.45M 66.57M 78.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -29 -33 -28 -32 -36 -39 -44 -45 -52 -61 -59
Normalized NOPAT Margin		 -1,902.92% -807.04% -18,221.54% -1,297.91% -1,143.47% -3,337.78% -6,319.04% -6,123.27% 0.00% -50,839.83% -394,030.00%
Pre Tax Income Margin		 0.00% -3,423.60% -21,030.77% 0.00% 0.00% -13,435.15% -7,740.43% -7,753.42% 0.00% -67,764.17% -524,566.67%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here are the notable trends for Celldex Therapeutics (CLDX) based on the last four years of quarterly statements. The focus is on what may be relevant to retail investors evaluating liquidity, profitability, and capital structure.

  • One-off liquidity boost from sale/maturity of investments: $116.9 million in Q3 2025 and $111.5 million in Q4 2025.
  • Consistent investing-cash inflows across multiple quarters, reflecting asset-sale proceeds: approximately +$42.95M (Q1 2025), +$49.85M (Q2 2025), +$60.42M (Q3 2025), and +$55.43M (Q4 2025) from continuing investing activities.
  • Modest equity financing activity in several quarters, providing additional liquidity (example issuances around hundreds of thousands to under a million in multiple periods).
  • Solid balance-sheet cushion as of recent quarter: Total assets about $648.4M and Total equity about $598.4M, with Total liabilities around $50M, indicating a relatively conservative liability profile.
  • Revenue remains very small and volatile, with Q4 2025 operating revenue of $120k and little-to-no sustained top-line growth over the period.
  • R&D continues to be the largest expense area in many quarters (e.g., Q4 2025: $75.3M; Q3 2025: $62.9M), suggesting ongoing investment in clinical pipelines but limited near-term profitability.
  • Weighted-average shares and earnings per share show ongoing dilution and negative earnings (e.g., Weighted-average shares around mid-66 million; EPS negative in recent quarters).
  • Net income/(loss) remains negative across quarters, with Q4 2025 net loss around $81.3M and sizable deficits continuing through 2023–2025 data.
  • Operating cash flow is negative in every recent quarter, reflecting ongoing cash burn (e.g., Q4 2025 net cash from continuing operating activities about -$63.9M).
  • Long-term sustainability concerns: Retained earnings are deeply negative across balance sheets, and equity issuance appears necessary to fund operations, indicating persistent dilution and ongoing deficits.
05/27/26 11:24 AM ETAI Generated. May Contain Errors.

Celldex Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Celldex Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Celldex Therapeutics' net income appears to be on an upward trend, with a most recent value of -$258.76 million in 2025, rising from -$127.20 million in 2015. The previous period was -$157.86 million in 2024. Find out what analysts predict for Celldex Therapeutics in the coming months.

Celldex Therapeutics' total operating income in 2025 was -$287.37 million, based on the following breakdown:
  • Total Gross Profit: $1.55 million
  • Total Operating Expenses: $288.91 million

Over the last 10 years, Celldex Therapeutics' total revenue changed from $5.48 million in 2015 to $1.55 million in 2025, a change of -71.8%.

Celldex Therapeutics' total liabilities were at $55.82 million at the end of 2025, a 23.1% increase from 2024, and a 17.6% increase since 2015.

In the past 10 years, Celldex Therapeutics' cash and equivalents has ranged from $11.23 million in 2019 to $72.11 million in 2015, and is currently $28.87 million as of their latest financial filing in 2025.

Over the last 10 years, Celldex Therapeutics' book value per share changed from 2.94 in 2015 to 7.93 in 2025, a change of 169.8%.


Related Companies

Financial statements for NASDAQ:CLDX last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel